What is your preferred first line therapy for ROS-1 rearranged metastatic NSCLC for patients presenting with CNS metastases?  

The recognition of ROS1 as a distinct actionable translocation in NSCLC, and approval of crizotinib in 2016 based upon an expansion cohort of the original phase I study of crizotinib (N Engl J Med. 2014 Nov 20;371(21):1963-71) was an important step.  Unfortunately, the limitations of crizotinib...